Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C

2021; Elsevier BV; Volume: 32; Linguagem: Inglês

10.1016/j.annonc.2021.08.1883

1569-8041

Rafał Dziadziuszko, Solange Peters, Shirish M. Gadgeel, Mariann Mathisen, Sarah M. Shagan, Enriqueta Felip, Alessandro Morabito, Parneet Cheema, Manuel Cobo, Z. Andric, C.H. Barrios, Masafumi Yamaguchi, Éric Dansin, Pongwut Danchaivijitr, Melissa L. Johnson, Silvia Novello, David R. Gandara, Erica Schleifman, J. Wang, Tony Mok,

Lymphoma Diagnosis and Treatment

TMB is a promising biomarker for immunotherapy in NSCLC, but current data are mostly retrospective. As not all pts may have sufficient tissue for comprehensive biomarker testing, bTMB was prospectively tested as a novel biomarker using targeted next-generation sequencing. BFAST (NCT03178552), a global, open-label, multi-cohort trial, evaluated safety and efficacy of targeted therapies or immunotherapy in biomarker-selected pts with unresectable mNSCLC. Here we present results from Cohort C of 1L atezo vs platinum-based chemo in pts with bTMB+ mNSCLC.